A new experimental drug from Kythera Biopharmaceuticals Inc. may be able to rid you of that pesky double chin.
The drug ATX-101, which is a version of the fat-destroying molecule deoxycholic acid, is injected into fat under the chin and contours the chin without affecting surrounding tissue.
It has so far been tested on 1,600 patients in clinical trials. More than 90% of whom maintained a meaningful reduction of fat after two years.
The drug is still not approved by the U.S. Food and Drug Administration and is currently under review by an outside panel of advisors and academics, with a decision expected on March 9th, 2015. The FDA, however, is not required to follow their recommendation.
If approved, ATX-101 would be the first injectable drug of its kind to target the chin area.
Chin augmentation was the fastest-growing category of plastic surgery in the United States in 2011, growing more than breast augmentations, Botox injections and liposuction treatments combined, according to the American Society of Plastic Surgeons.
The FDA is scheduled to rule on the drug on May 13, 2015.